Europe Branded Generics Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

TABLE 1 BRAND COMPARATIVE ANALYSIS OF THE EUROPE BRANDED GENERICS MARKET

TABLE 2 PATENT LANDSCAPE

TABLE 3 EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 4 EUROPE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 5 EUROPE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 6 EUROPE DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 7 EUROPE ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 EUROPE ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 9 EUROPE BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 10 EUROPE CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 EUROPE DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 12 EUROPE ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 13 EUROPE CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 EUROPE HORMONES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 15 EUROPE HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 16 EUROPE STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 17 EUROPE SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 18 EUROPE ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 19 EUROPE PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 20 EUROPE ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 EUROPE THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 22 EUROPE OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 23 EUROPE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 24 EUROPE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 25 EUROPE PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 26 EUROPE PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 27 EUROPE FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 28 EUROPE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 29 EUROPE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 EUROPE STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 31 EUROPE COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 32 EUROPE FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 33 EUROPE BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 34 EUROPE PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 EUROPE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 36 EUROPE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 37 EUROPE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 38 EUROPE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 39 EUROPE NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 40 EUROPE NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 EUROPE ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 42 EUROPE TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 43 EUROPE ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 44 EUROPE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 45 EUROPE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 46 EUROPE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 47 EUROPE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 48 EUROPE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 49 EUROPE ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 50 EUROPE MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 EUROPE NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 52 EUROPE ANTI-PSYCHOTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 EUROPE ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 EUROPE SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 55 EUROPE FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 56 EUROPE PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 57 EUROPE THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 58 EUROPE NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 59 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 60 EUROPE BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 61 EUROPE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 62 EUROPE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 EUROPE PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 64 EUROPE PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 EUROPE ONCOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 66 EUROPE ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 EUROPE SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 EUROPE HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 69 EUROPE DIABETES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 70 EUROPE DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 71 EUROPE NEUROLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 72 EUROPE NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 73 EUROPE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 74 EUROPE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 75 EUROPE DERMATOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 76 EUROPE DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 78 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 79 EUROPE BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 80 EUROPE ORAL IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 81 EUROPE ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 EUROPE INJECTABLE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 83 EUROPE INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 84 EUROPE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 85 EUROPE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 86 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 87 EUROPE BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 88 EUROPE VALUE-ADDED BRANDED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 89 EUROPE TRADE NAMED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 90 EUROPE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 91 EUROPE ADULT IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 92 EUROPE GERIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 93 EUROPE PEDIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 94 EUROPE BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 95 EUROPE HOSPITALS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 96 EUROPE CLINICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 97 EUROPE HOMECARE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 98 EUROPE ACADEMIC & RESEARCH INSTITUTES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 99 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 100 EUROPE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 101 EUROPE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 102 EUROPE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 103 EUROPE HOSPITAL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 104 EUROPE DIRECT TENDERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 105 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 106 EUROPE BRANDED GENERICS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 107 EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 108 EUROPE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 EUROPE DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 EUROPE ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 EUROPE ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 EUROPE BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 113 EUROPE CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 114 EUROPE DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 EUROPE ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 EUROPE CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 EUROPE HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 118 EUROPE STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 EUROPE SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 EUROPE ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 121 EUROPE PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 EUROPE ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 EUROPE THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 124 EUROPE OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 EUROPE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 EUROPE PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 EUROPE PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 128 EUROPE FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 EUROPE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 130 EUROPE STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 131 EUROPE COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 EUROPE FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 133 EUROPE BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 134 EUROPE PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 135 EUROPE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 136 EUROPE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 EUROPE NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 138 EUROPE NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 139 EUROPE ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 EUROPE TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 141 EUROPE ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 142 EUROPE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 EUROPE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 144 EUROPE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 145 EUROPE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 EUROPE ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 147 EUROPE MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 148 EUROPE NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 149 EUROPE ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 EUROPE SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 EUROPE FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 EUROPE PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 153 EUROPE THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 EUROPE NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 EUROPE BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 156 EUROPE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 EUROPE PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 EUROPE ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 EUROPE SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 160 EUROPE HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 EUROPE DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 162 EUROPE NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 163 EUROPE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 164 EUROPE DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 166 EUROPE BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 167 EUROPE ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 168 EUROPE INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 EUROPE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 EUROPE BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 171 EUROPE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 172 EUROPE BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 173 EUROPE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 174 EUROPE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 GERMANY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 176 GERMANY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 GERMANY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 178 GERMANY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 GERMANY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 180 GERMANY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 181 GERMANY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 GERMANY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 183 GERMANY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 184 GERMANY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 GERMANY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 186 GERMANY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 187 GERMANY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 188 GERMANY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 189 GERMANY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 GERMANY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 191 GERMANY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 192 GERMANY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 193 GERMANY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 GERMANY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 195 GERMANY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 GERMANY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 197 GERMANY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 198 GERMANY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 199 GERMANY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 GERMANY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 GERMANY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 GERMANY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 203 GERMANY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 GERMANY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 GERMANY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 GERMANY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 207 GERMANY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 GERMANY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 209 GERMANY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 210 GERMANY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 GERMANY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 GERMANY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 213 GERMANY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 214 GERMANY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 GERMANY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 GERMANY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 GERMANY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 218 GERMANY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 GERMANY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 GERMANY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 221 GERMANY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 GERMANY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 GERMANY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 224 GERMANY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 GERMANY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 GERMANY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 GERMANY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 228 GERMANY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 GERMANY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 230 GERMANY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 231 GERMANY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 GERMANY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 233 GERMANY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 234 GERMANY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 235 GERMANY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 236 GERMANY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 GERMANY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 238 GERMANY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 239 GERMANY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 240 GERMANY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 241 GERMANY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 242 GERMANY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 UNITED KINGDOM BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 244 UNITED KINGDOM ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 245 UNITED KINGDOM DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 UNITED KINGDOM ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 247 UNITED KINGDOM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 248 UNITED KINGDOM BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 249 UNITED KINGDOM CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 UNITED KINGDOM DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 UNITED KINGDOM ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 UNITED KINGDOM CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 253 UNITED KINGDOM HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 UNITED KINGDOM STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 UNITED KINGDOM SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 UNITED KINGDOM ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 257 UNITED KINGDOM PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 258 UNITED KINGDOM ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 UNITED KINGDOM THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 UNITED KINGDOM OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 261 UNITED KINGDOM ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 262 UNITED KINGDOM PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 263 UNITED KINGDOM PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 264 UNITED KINGDOM FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 265 UNITED KINGDOM LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 UNITED KINGDOM STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 UNITED KINGDOM COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 268 UNITED KINGDOM FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 UNITED KINGDOM BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 UNITED KINGDOM PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 271 UNITED KINGDOM ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 UNITED KINGDOM ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 UNITED KINGDOM NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 274 UNITED KINGDOM NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 UNITED KINGDOM ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 UNITED KINGDOM TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 UNITED KINGDOM ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 278 UNITED KINGDOM ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 UNITED KINGDOM SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 280 UNITED KINGDOM SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 281 UNITED KINGDOM TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 UNITED KINGDOM ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 283 UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 284 UNITED KINGDOM NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 UNITED KINGDOM ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 286 UNITED KINGDOM SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 287 UNITED KINGDOM FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 288 UNITED KINGDOM PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 289 UNITED KINGDOM THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 290 UNITED KINGDOM NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 291 UNITED KINGDOM BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 292 UNITED KINGDOM CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 293 UNITED KINGDOM PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 294 UNITED KINGDOM ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 295 UNITED KINGDOM SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 UNITED KINGDOM HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 297 UNITED KINGDOM DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 298 UNITED KINGDOM NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 299 UNITED KINGDOM GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 UNITED KINGDOM DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 301 UNITED KINGDOM OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 UNITED KINGDOM BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 303 UNITED KINGDOM ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 UNITED KINGDOM INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 UNITED KINGDOM TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 UNITED KINGDOM BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 UNITED KINGDOM BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 308 UNITED KINGDOM BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 309 UNITED KINGDOM BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 310 UNITED KINGDOM RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 311 ITALY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 312 ITALY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 313 ITALY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 314 ITALY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 315 ITALY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 316 ITALY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 317 ITALY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 318 ITALY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 ITALY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 ITALY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 321 ITALY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 322 ITALY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 323 ITALY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 ITALY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 ITALY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 ITALY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 ITALY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 328 ITALY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 ITALY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 330 ITALY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 ITALY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 332 ITALY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 333 ITALY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 334 ITALY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 ITALY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 336 ITALY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 ITALY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 338 ITALY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 339 ITALY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 340 ITALY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 341 ITALY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 342 ITALY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 ITALY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 344 ITALY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 345 ITALY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 ITALY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 347 ITALY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 348 ITALY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 349 ITALY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 ITALY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 ITALY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 ITALY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 353 ITALY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 ITALY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 ITALY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 ITALY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 ITALY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 ITALY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 ITALY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 360 ITALY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 ITALY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 ITALY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 363 ITALY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 364 ITALY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 365 ITALY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 ITALY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 367 ITALY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 368 ITALY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 369 ITALY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 ITALY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 371 ITALY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 ITALY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 ITALY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 374 ITALY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 ITALY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 376 ITALY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 377 ITALY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 378 ITALY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 FRANCE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 380 FRANCE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 381 FRANCE DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 FRANCE ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 383 FRANCE ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 384 FRANCE BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 FRANCE CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 386 FRANCE DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 FRANCE ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 388 FRANCE CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 389 FRANCE HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 390 FRANCE STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 391 FRANCE SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 392 FRANCE ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 FRANCE PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 394 FRANCE ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 395 FRANCE THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 396 FRANCE OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 397 FRANCE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 398 FRANCE PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 399 FRANCE PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 400 FRANCE FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 FRANCE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 402 FRANCE STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 403 FRANCE COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 404 FRANCE FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 405 FRANCE BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 406 FRANCE PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 407 FRANCE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 FRANCE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 409 FRANCE NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 410 FRANCE NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 FRANCE ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 412 FRANCE TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 413 FRANCE ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 414 FRANCE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 FRANCE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 FRANCE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 417 FRANCE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 418 FRANCE ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 419 FRANCE MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 420 FRANCE NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 421 FRANCE ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 FRANCE SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 423 FRANCE FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 424 FRANCE PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 425 FRANCE THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 FRANCE NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 427 FRANCE BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 428 FRANCE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 429 FRANCE PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 430 FRANCE ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 431 FRANCE SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 432 FRANCE HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 433 FRANCE DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 434 FRANCE NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 435 FRANCE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 436 FRANCE DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 FRANCE OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 438 FRANCE BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 439 FRANCE ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 440 FRANCE INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 441 FRANCE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 442 FRANCE BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 443 FRANCE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 444 FRANCE BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 445 FRANCE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 446 FRANCE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 447 SPAIN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 448 SPAIN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 449 SPAIN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 450 SPAIN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 451 SPAIN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 452 SPAIN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 453 SPAIN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 454 SPAIN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 455 SPAIN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 456 SPAIN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 457 SPAIN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 458 SPAIN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 459 SPAIN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 460 SPAIN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 461 SPAIN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 462 SPAIN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 463 SPAIN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 464 SPAIN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 465 SPAIN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 466 SPAIN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 467 SPAIN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 468 SPAIN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 469 SPAIN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 470 SPAIN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 471 SPAIN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 472 SPAIN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 473 SPAIN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 474 SPAIN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 475 SPAIN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 476 SPAIN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 477 SPAIN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 478 SPAIN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 479 SPAIN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 480 SPAIN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 481 SPAIN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 482 SPAIN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 483 SPAIN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 484 SPAIN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 485 SPAIN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 486 SPAIN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 487 SPAIN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 488 SPAIN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 489 SPAIN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 490 SPAIN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 491 SPAIN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 492 SPAIN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 493 SPAIN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 494 SPAIN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 495 SPAIN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 496 SPAIN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 497 SPAIN PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 498 SPAIN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 499 SPAIN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 500 SPAIN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 501 SPAIN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 502 SPAIN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 503 SPAIN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 504 SPAIN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 505 SPAIN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 506 SPAIN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 507 SPAIN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 508 SPAIN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 509 SPAIN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 510 SPAIN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 511 SPAIN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 512 SPAIN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 513 SPAIN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 514 SPAIN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 515 TURKEY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 516 TURKEY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 517 TURKEY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 518 TURKEY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 519 TURKEY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 520 TURKEY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 521 TURKEY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 522 TURKEY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 523 TURKEY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 524 TURKEY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 525 TURKEY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 526 TURKEY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 527 TURKEY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 528 TURKEY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 529 TURKEY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 530 TURKEY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 531 TURKEY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 532 TURKEY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 533 TURKEY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 534 TURKEY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 535 TURKEY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 536 TURKEY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 537 TURKEY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 538 TURKEY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 539 TURKEY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 540 TURKEY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 541 TURKEY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 542 TURKEY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 543 TURKEY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 544 TURKEY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 545 TURKEY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 546 TURKEY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 547 TURKEY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 548 TURKEY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 549 TURKEY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 550 TURKEY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 551 TURKEY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 552 TURKEY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 553 TURKEY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 554 TURKEY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 555 TURKEY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 556 TURKEY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 557 TURKEY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 558 TURKEY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 559 TURKEY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 560 TURKEY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 561 TURKEY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 562 TURKEY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 563 TURKEY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 564 TURKEY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 565 TURKEY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 566 TURKEY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 567 TURKEY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 568 TURKEY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 569 TURKEY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 570 TURKEY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 571 TURKEY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 572 TURKEY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 573 TURKEY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 574 TURKEY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 575 TURKEY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 576 TURKEY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 577 TURKEY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 578 TURKEY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 579 TURKEY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 580 TURKEY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 581 TURKEY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 582 TURKEY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 583 RUSSIA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 584 RUSSIA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 585 RUSSIA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 586 RUSSIA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 587 RUSSIA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 588 RUSSIA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 589 RUSSIA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 590 RUSSIA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 591 RUSSIA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 592 RUSSIA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 593 RUSSIA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 594 RUSSIA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 595 RUSSIA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 596 RUSSIA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 597 RUSSIA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 598 RUSSIA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 599 RUSSIA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 600 RUSSIA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 601 RUSSIA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 602 RUSSIA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 603 RUSSIA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 604 RUSSIA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 605 RUSSIA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 606 RUSSIA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 607 RUSSIA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 608 RUSSIA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 609 RUSSIA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 610 RUSSIA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 611 RUSSIA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 612 RUSSIA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 613 RUSSIA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 614 RUSSIA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 615 RUSSIA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 616 RUSSIA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 617 RUSSIA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 618 RUSSIA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 619 RUSSIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 620 RUSSIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 621 RUSSIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 622 RUSSIA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 623 RUSSIA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 624 RUSSIA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 625 RUSSIA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 626 RUSSIA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 627 RUSSIA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 628 RUSSIA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 629 RUSSIA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 630 RUSSIA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 631 RUSSIA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 632 RUSSIA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 633 RUSSIA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 634 RUSSIA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 635 RUSSIA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 636 RUSSIA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 637 RUSSIA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 638 RUSSIA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 639 RUSSIA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 640 RUSSIA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 641 RUSSIA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 642 RUSSIA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 643 RUSSIA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 644 RUSSIA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 645 RUSSIA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 646 RUSSIA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 647 RUSSIA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 648 RUSSIA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 649 RUSSIA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 650 RUSSIA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 651 SWITZERLAND BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 652 SWITZERLAND ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 653 SWITZERLAND DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 654 SWITZERLAND ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 655 SWITZERLAND ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 656 SWITZERLAND BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 657 SWITZERLAND CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 658 SWITZERLAND DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 659 SWITZERLAND ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 660 SWITZERLAND CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 661 SWITZERLAND HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 662 SWITZERLAND STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 663 SWITZERLAND SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 664 SWITZERLAND ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 665 SWITZERLAND PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 666 SWITZERLAND ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 667 SWITZERLAND THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 668 SWITZERLAND OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 669 SWITZERLAND ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 670 SWITZERLAND PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 671 SWITZERLAND PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 672 SWITZERLAND FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 673 SWITZERLAND LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 674 SWITZERLAND STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 675 SWITZERLAND COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 676 SWITZERLAND FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 677 SWITZERLAND BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 678 SWITZERLAND PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 679 SWITZERLAND ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 680 SWITZERLAND ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 681 SWITZERLAND NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 682 SWITZERLAND NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 683 SWITZERLAND ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 684 SWITZERLAND TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 685 SWITZERLAND ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 686 SWITZERLAND ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 687 SWITZERLAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 688 SWITZERLAND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 689 SWITZERLAND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 690 SWITZERLAND ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 691 SWITZERLAND MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 692 SWITZERLAND NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 693 SWITZERLAND ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 694 SWITZERLAND SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 695 SWITZERLAND FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 696 SWITZERLAND PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 697 SWITZERLAND THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 698 SWITZERLAND NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 699 SWITZERLAND BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 700 SWITZERLAND CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 701 SWITZERLAND PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 702 SWITZERLAND ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 703 SWITZERLAND SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 704 SWITZERLAND HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 705 SWITZERLAND DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 706 SWITZERLAND NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 707 SWITZERLAND GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 708 SWITZERLAND DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 709 SWITZERLAND OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 710 SWITZERLAND BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 711 SWITZERLAND ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 712 SWITZERLAND INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 713 SWITZERLAND TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 714 SWITZERLAND BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 715 SWITZERLAND BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 716 SWITZERLAND BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 717 SWITZERLAND BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 718 SWITZERLAND RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 719 NETHERLANDS BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 720 NETHERLANDS ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 721 NETHERLANDS DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 722 NETHERLANDS ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 723 NETHERLANDS ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 724 NETHERLANDS BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 725 NETHERLANDS CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 726 NETHERLANDS DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 727 NETHERLANDS ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 728 NETHERLANDS CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 729 NETHERLANDS HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 730 NETHERLANDS STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 731 NETHERLANDS SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 732 NETHERLANDS ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 733 NETHERLANDS PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 734 NETHERLANDS ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 735 NETHERLANDS THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 736 NETHERLANDS OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 737 NETHERLANDS ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 738 NETHERLANDS PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 739 NETHERLANDS PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 740 NETHERLANDS FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 741 NETHERLANDS LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 742 NETHERLANDS STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 743 NETHERLANDS COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 744 NETHERLANDS FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 745 NETHERLANDS BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 746 NETHERLANDS PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 747 NETHERLANDS ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 748 NETHERLANDS ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 749 NETHERLANDS NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 750 NETHERLANDS NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 751 NETHERLANDS ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 752 NETHERLANDS TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 753 NETHERLANDS ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 754 NETHERLANDS ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 755 NETHERLANDS SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 756 NETHERLANDS SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 757 NETHERLANDS TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 758 NETHERLANDS ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 759 NETHERLANDS MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 760 NETHERLANDS NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 761 NETHERLANDS ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 762 NETHERLANDS SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 763 NETHERLANDS FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 764 NETHERLANDS PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 765 NETHERLANDS THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 766 NETHERLANDS NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 767 NETHERLANDS BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 768 NETHERLANDS CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 769 NETHERLANDS PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 770 NETHERLANDS ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 771 NETHERLANDS SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 772 NETHERLANDS HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 773 NETHERLANDS DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 774 NETHERLANDS NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 775 NETHERLANDS GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 776 NETHERLANDS DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 777 NETHERLANDS OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 778 NETHERLANDS BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 779 NETHERLANDS ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 780 NETHERLANDS INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 781 NETHERLANDS TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 782 NETHERLANDS BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 783 NETHERLANDS BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 784 NETHERLANDS BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 785 NETHERLANDS BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 786 NETHERLANDS RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 787 BELGIUM BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 788 BELGIUM ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 789 BELGIUM DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 790 BELGIUM ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 791 BELGIUM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 792 BELGIUM BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 793 BELGIUM CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 794 BELGIUM DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 795 BELGIUM ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 796 BELGIUM CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 797 BELGIUM HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 798 BELGIUM STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 799 BELGIUM SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 800 BELGIUM ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 801 BELGIUM PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 802 BELGIUM ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 803 BELGIUM THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 804 BELGIUM OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 805 BELGIUM ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 806 BELGIUM PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 807 BELGIUM PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 808 BELGIUM FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 809 BELGIUM LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 810 BELGIUM STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 811 BELGIUM COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 812 BELGIUM FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 813 BELGIUM BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 814 BELGIUM PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 815 BELGIUM ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 816 BELGIUM ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 817 BELGIUM NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 818 BELGIUM NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 819 BELGIUM ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 820 BELGIUM TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 821 BELGIUM ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 822 BELGIUM ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 823 BELGIUM SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 824 BELGIUM SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 825 BELGIUM TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 826 BELGIUM ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 827 BELGIUM MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 828 BELGIUM NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 829 BELGIUM ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 830 BELGIUM SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 831 BELGIUM FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 832 BELGIUM PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 833 BELGIUM THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 834 BELGIUM NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 835 BELGIUM BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 836 BELGIUM CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 837 BELGIUM PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 838 BELGIUM ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 839 BELGIUM SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 840 BELGIUM HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 841 BELGIUM DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 842 BELGIUM NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 843 BELGIUM GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 844 BELGIUM DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 845 BELGIUM OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 846 BELGIUM BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 847 BELGIUM ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 848 BELGIUM INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 849 BELGIUM TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 850 BELGIUM BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 851 BELGIUM BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 852 BELGIUM BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 853 BELGIUM BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 854 BELGIUM RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 855 SWEDEN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 856 SWEDEN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 857 SWEDEN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 858 SWEDEN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 859 SWEDEN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 860 SWEDEN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 861 SWEDEN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 862 SWEDEN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 863 SWEDEN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 864 SWEDEN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 865 SWEDEN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 866 SWEDEN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 867 SWEDEN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 868 SWEDEN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 869 SWEDEN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 870 SWEDEN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 871 SWEDEN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 872 SWEDEN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 873 SWEDEN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 874 SWEDEN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 875 SWEDEN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 876 SWEDEN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 877 SWEDEN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 878 SWEDEN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 879 SWEDEN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 880 SWEDEN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 881 SWEDEN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 882 SWEDEN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 883 SWEDEN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 884 SWEDEN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 885 SWEDEN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 886 SWEDEN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 887 SWEDEN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 888 SWEDEN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 889 SWEDEN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 890 SWEDEN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 891 SWEDEN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 892 SWEDEN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 893 SWEDEN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 894 SWEDEN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 895 SWEDEN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 896 SWEDEN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 897 SWEDEN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 898 SWEDEN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 899 SWEDEN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 900 SWEDEN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 901 SWEDEN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 902 SWEDEN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 903 SWEDEN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 904 SWEDEN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 905 SWEDEN PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 906 SWEDEN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 907 SWEDEN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 908 SWEDEN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 909 SWEDEN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 910 SWEDEN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 911 SWEDEN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 912 SWEDEN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 913 SWEDEN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 914 SWEDEN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 915 SWEDEN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 916 SWEDEN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 917 SWEDEN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 918 SWEDEN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 919 SWEDEN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 920 SWEDEN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 921 SWEDEN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 922 SWEDEN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 923 DENMARK BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 924 DENMARK ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 925 DENMARK DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 926 DENMARK ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 927 DENMARK ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 928 DENMARK BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 929 DENMARK CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 930 DENMARK DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 931 DENMARK ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 932 DENMARK CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 933 DENMARK HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 934 DENMARK STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 935 DENMARK SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 936 DENMARK ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 937 DENMARK PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 938 DENMARK ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 939 DENMARK THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 940 DENMARK OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 941 DENMARK ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 942 DENMARK PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 943 DENMARK PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 944 DENMARK FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 945 DENMARK LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 946 DENMARK STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 947 DENMARK COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 948 DENMARK FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 949 DENMARK BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 950 DENMARK PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 951 DENMARK ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 952 DENMARK ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 953 DENMARK NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 954 DENMARK NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 955 DENMARK ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 956 DENMARK TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 957 DENMARK ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 958 DENMARK ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 959 DENMARK SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 960 DENMARK SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 961 DENMARK TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 962 DENMARK ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 963 DENMARK MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 964 DENMARK NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 965 DENMARK ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 966 DENMARK SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 967 DENMARK FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 968 DENMARK PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 969 DENMARK THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 970 DENMARK NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 971 DENMARK BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 972 DENMARK CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 973 DENMARK PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 974 DENMARK ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 975 DENMARK SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 976 DENMARK HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 977 DENMARK DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 978 DENMARK NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 979 DENMARK GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 980 DENMARK DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 981 DENMARK OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 982 DENMARK BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 983 DENMARK ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 984 DENMARK INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 985 DENMARK TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 986 DENMARK BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 987 DENMARK BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 988 DENMARK BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 989 DENMARK BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 990 DENMARK RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 991 NORWAY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 992 NORWAY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 993 NORWAY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 994 NORWAY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 995 NORWAY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 996 NORWAY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 997 NORWAY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 998 NORWAY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 999 NORWAY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1000 NORWAY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1001 NORWAY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1002 NORWAY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1003 NORWAY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1004 NORWAY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1005 NORWAY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1006 NORWAY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1007 NORWAY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1008 NORWAY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1009 NORWAY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1010 NORWAY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1011 NORWAY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1012 NORWAY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1013 NORWAY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1014 NORWAY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1015 NORWAY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1016 NORWAY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1017 NORWAY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1018 NORWAY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1019 NORWAY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1020 NORWAY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1021 NORWAY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1022 NORWAY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1023 NORWAY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1024 NORWAY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1025 NORWAY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1026 NORWAY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1027 NORWAY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1028 NORWAY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1029 NORWAY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1030 NORWAY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1031 NORWAY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1032 NORWAY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1033 NORWAY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1034 NORWAY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1035 NORWAY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1036 NORWAY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1037 NORWAY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1038 NORWAY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1039 NORWAY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 1040 NORWAY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1041 NORWAY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1042 NORWAY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1043 NORWAY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1044 NORWAY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1045 NORWAY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1046 NORWAY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1047 NORWAY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1048 NORWAY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1049 NORWAY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1050 NORWAY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 1051 NORWAY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1052 NORWAY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1053 NORWAY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1054 NORWAY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 1055 NORWAY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 1056 NORWAY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 1057 NORWAY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 1058 NORWAY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1059 FINLAND BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 1060 FINLAND ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1061 FINLAND DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1062 FINLAND ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1063 FINLAND ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1064 FINLAND BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1065 FINLAND CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1066 FINLAND DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1067 FINLAND ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1068 FINLAND CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1069 FINLAND HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1070 FINLAND STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1071 FINLAND SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1072 FINLAND ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1073 FINLAND PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1074 FINLAND ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1075 FINLAND THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1076 FINLAND OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1077 FINLAND ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1078 FINLAND PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1079 FINLAND PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1080 FINLAND FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1081 FINLAND LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1082 FINLAND STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1083 FINLAND COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1084 FINLAND FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1085 FINLAND BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1086 FINLAND PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1087 FINLAND ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1088 FINLAND ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1089 FINLAND NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1090 FINLAND NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1091 FINLAND ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1092 FINLAND TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1093 FINLAND ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1094 FINLAND ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1095 FINLAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1096 FINLAND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1097 FINLAND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1098 FINLAND ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1099 FINLAND MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1100 FINLAND NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1101 FINLAND ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1102 FINLAND SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1103 FINLAND FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1104 FINLAND PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1105 FINLAND THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1106 FINLAND NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1107 FINLAND BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 1108 FINLAND CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1109 FINLAND PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1110 FINLAND ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1111 FINLAND SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1112 FINLAND HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1113 FINLAND DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1114 FINLAND NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1115 FINLAND GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1116 FINLAND DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1117 FINLAND OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1118 FINLAND BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 1119 FINLAND ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1120 FINLAND INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1121 FINLAND TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1122 FINLAND BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 1123 FINLAND BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 1124 FINLAND BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 1125 FINLAND BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 1126 FINLAND RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1127 REST OF EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)